The FDA's 503B Bulks List Decision: What Happens to Compounded GLP-1s After June 2026

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. If finalized, this would close the last remaining legal pathway for large-scale compounding of GLP-1 medications by outsourcing facilities. Public comments close June 29, 2026.

If you're currently getting compounded GLP-1 medication through a telehealth platform, you need to understand what this means — and what it doesn't.

What the 503B Bulks List Actually Is

Section 503B of the Federal Food, Drug, and Cosmetic Act allows FDA-registered outsourcing facilities to compound drugs without individual patient prescriptions — essentially enabling larger-scale production. But these facilities can only compound using bulk drug substances (active pharmaceutical ingredients) that appear on the 503B bulks list, or drugs that are on the FDA's drug shortage list.

During the GLP-1 shortages that stretched from 2022 through early 2025, both pathways were open. Semaglutide was on the shortage list until February 2025. Tirzepatide until October 2024. That's how the compounded GLP-1 telehealth industry reached roughly 30% of U.S. supply at its peak in 2024.

Now both pathways are closing:

What the FDA Said

The FDA evaluated nominations to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list and concluded there is no demonstrated clinical need for outsourcing facilities to compound these drugs from bulk substances. Commissioner Makary stated: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."

Critically, the FDA explicitly rejected the argument that affordability or insurance access constitutes "clinical need" under the statute. That's a legal determination, not a clinical one — and it has enormous implications for the millions of patients who turned to compounded GLP-1s specifically because they couldn't afford brand-name options.

What This Does and Doesn't Affect

Affected: 503B Outsourcing Facilities

If finalized, 503B outsourcing facilities would lose both legal pathways to compound semaglutide and tirzepatide. No shortage list. No bulks list. This would directly impact the large-scale telehealth platforms that rely on 503B compounding for volume production.

Not Affected: 503A Compounding Pharmacies

Traditional 503A compounding pharmacies — which prepare patient-specific prescriptions based on individual prescriber orders — are not directly affected by this proposal. They operate under different statutory authority. However, 503A pharmacies cannot replicate the scale of 503B operations, so the practical availability of compounded GLP-1s would shrink significantly.

Three Scenarios After June 29

Most Likely: Full Exclusion

The FDA finalizes the proposal as-is. 503B compounding of semaglutide, tirzepatide, and liraglutide ends (outside of any future shortage). Telehealth platforms shift to 503A pharmacy partnerships, brand-name dispensing, or both. Patient access narrows. Prices may rise for compounded options due to reduced scale.

Possible: Partial Exception

The FDA modifies the proposal based on comments — potentially allowing certain formulations (like alternative dosage forms not commercially available) or creating a transition period. This would require compelling clinical-need evidence in the comment docket.

Unlikely: Reversal

The FDA reverses course entirely. Given the enforcement trajectory — thousands of warning letters, a DOJ referral, Commissioner Makary's explicit statements — this would represent a dramatic policy reversal that nothing in the current regulatory posture suggests.

What to Do Right Now

If you're on a compounded GLP-1 through a telehealth platform, don't panic. Whatever happens after June 29, your current supply isn't being recalled. But this is the right time to understand your options.